Home  »  Business   »  Alpine Immune Sciences Inc. (NASDAQ: ALPN) –...

Alpine Immune Sciences Inc. (NASDAQ: ALPN) – Analysts’ Opinion Is Improving

Alpine Immune Sciences Inc. (NASDAQ:ALPN) traded at $7.07 at close of the session on Wednesday, September 21, made a downward move of -3.81% on its previous day’s price.

Looking at the stock we see that its previous close was $7.35 and the beta (5Y monthly) reads 1.72 with the day’s price range being $7.20 – $7.60. In terms of its 52-week price range, ALPN has a high of $14.40 and a low of $6.00. The company’s stock has lost about -10.04% over that past 30 days.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

Alpine Immune Sciences Inc. has a market cap of $222.12 million and is expected to release its quarterly earnings report on Mar 16, 2022 – Mar 21, 2022. Estimates by analysts give the company expected earnings per share (EPS) of -$0.39, with the EPS growth for the year raised at -$0.91 for 2022 and -$1.69 for next year. These figures represent 54.00% and -85.70% growth in EPS for the two years respectively.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $10.04 million, with a low of $4.6 million and a high of $15.32 million. The median projection represents growth squeezing down to 39.60% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $62.4 million, or 166.20% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the ALPN stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 4 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Alpine Immune Sciences Inc. (ALPN) stock as a Hold, while 4 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is -11.35% off its SMA20 and -15.17% from its 50-day simple moving average. The RSI (14) is pointing at 34.24 while the volatility over the past week is 6.84% and jumps to 5.65% over the past one month. The beta value is 1.56, while the average true range (ATR) is currently pointing at 0.47. The average price target for the stock over the next 12 months is $21.00, with the estimates having a low of $17.00 and a high of $25.00. These price ends are -140.45% and -253.61% off the current price level respectively, although investors could be excited at the prospect of a -197.03% if the ALPN share price touches on the median price of $21.00.

Let’s briefly compare Alpine Immune Sciences Inc. (ALPN) stock to its peers. We find that current price change of -3.81% and -23.36% over the past 12 months for ALPN. Another of its peers Myriad Genetics Inc. (MYGN) has gained 0.77% previous session, and was -37.46% down over the past year. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 0.46% and 0.45%, respectively, at close of the trading.

Coming back to Alpine Immune Sciences Inc. (NASDAQ:ALPN), we note that the average 3-month trading volume was 59.14K, while that of the preceding 10-day period stands at 40220.0. Current shares outstanding are 30.32 million.

The insiders hold 0.80% of the company’s shares while institutions hold 79.60%. The data shows that short shares as of Jul 14, 2022, stood at 1.4 million at a short ratio of 13.52. This represents a 4.62% short interest in shares outstanding on Jul 14, 2022. Shares short fall in July from the previous month at 1.48 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -46.93% down in year-to-date price movement.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]